Meniere's disease is a chronic vestibular disorder that affects the inner ear, leading to symptoms such as vertigo, tinnitus, hearing loss, and a feeling of fullness in the ear. While there is no cure for Meniere's disease, several companies are involved in the development and distribution of medical devices, pharmaceuticals, and therapies aimed at managing its symptoms.
Disclaimer: List of key companies in no particular orderLatest Meniere's disease Companies Update
June 2023: The respiratory syncytial virus (RSV) vaccination for older individuals has been approved by the U.S. Food and Drug Administration (FDA). This is the second attempt to prevent the common respiratory illness that can be fatal for seniors. Pfizer Inc. makes the vaccine. The FDA authorized a comparable shot manufactured by competitor GSK Plc less than a month before its clearance. According to the business, Pfizer's vaccine is approved for use in adults 60 and older, the same age range as GSK's. The widespread availability of these boosters may be particularly beneficial to Pfizer, a company that has suffered due to a steep drop in sales of its antivirals and COVID-19 vaccination following a spike during the epidemic. Before making any decisions on cost-cutting measures, the corporation is awaiting the results of the purchases of both items this quarter.
Mar 2023: After Otonomy's dissolution was approved by stockholders, Spiral Therapeutics, Inc.—a clinical-stage firm focused on delivering medicines for inner ear disorders—announced today that it has completed the acquisition of certain assets from Otonomy, Inc. Preclinical and clinical data for OTO-104 (OTIVIDEX), a sustained-exposure dexamethasone formulation; patent rights, data, and know-how for OTO-510, an otoprotectant; and preclinical and clinical data, inventory, and information for OTO-413, a sustained-exposure Brain-Derived Neurotrophic Factor (BNDF) formulation are all included in the transaction. Spiral intends to expedite SPT-2101's road to late-stage clinical studies by utilizing the insightful data and important knowledge that Otonomy has accumulated over 15 years in the field of inner ear problems. This will also encourage further innovation around Spiral's innovative drug delivery platform. SPT-2101, the company's flagship candidate, is a patented sustained-release steroid formulation that uses cutting-edge drug delivery technology to be administered precisely into the inner ear. The goal of the current Phase 2 extension experiment for Ménière's disease is to learn more about the impact size of SPT-2101 administered once.
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)